Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Dec 9, 2025
Date Accepted: Feb 25, 2026

The final, peer-reviewed published version of this preprint can be found here:

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

Tanriover MD, Poulimeneas D, Tsopela GC, Kopsidas I, Argyropoulos C, Di Marzo R, Valdenmaiier O, Jakobsen SF, Valle-Simon P, Carcas-Sansuan AJ, Olesen OF, Cornely OA, Pana ZD, Zaoutis TE, Akova M

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

JMIR Public Health Surveill 2026;12:e89025

DOI: 10.2196/89025

PMID: 41945868

Barriers and opportunities to include underrepresented population groups in vaccine trials: a cross-sectional, observational, online survey study from VACCELERATE Research Network

  • Mine Durusu Tanriover; 
  • Dimitris Poulimeneas; 
  • Grammatiki-Christina Tsopela; 
  • Ioannis Kopsidas; 
  • Christos Argyropoulos; 
  • Romina Di Marzo; 
  • Olena Valdenmaiier; 
  • Stine Finne Jakobsen; 
  • Paula Valle-Simon; 
  • Antonio Javier Carcas-Sansuan; 
  • Ole F. Olesen; 
  • Oliver A. Cornely; 
  • Zoi Dorothea Pana; 
  • Theoklis E. Zaoutis; 
  • Murat Akova

ABSTRACT

Background:

Despite the vast growth of vaccine studies during the SARS-CoV-2 pandemic, clinical trials failed to represent diverse societal groups, including “underserved” or “hard-to-reach” groups. Understanding the factors hampering participation in vaccine clinical trials may facilitate better promotion of the VACCELERATE Volunteer Registry and enhance future access and engagement of volunteers in clinical trials.

Objective:

We aimed to decipher the causes of underrepresentation in vaccine trials by examining access mechanisms as experienced by professionals with expertise in vaccines/ vaccine trials.

Methods:

An online questionnaire was developed to gather personal information, group-specific barriers to vaccine trial participation and suggestions to overcome these barriers. Data are presented as absolute (n) and relative frequencies (%).

Results:

Hundred and fifteen respondents, the majority of whom were working in the scientific community (63.5%) completed the online survey. Challenges in recruiting children were identified due to “safety/efficacy concerns”, “difficulties about ethics and regulatory issues” and “lack of targeted information and communication”. Challenges in recruiting pregnant and lactating women (PLW) were primarily “ethics and regulatory requirements”, “safety issues” and “lack of prioritization/interest”. “Lack of information and communication channels adapted to the specific target group’’ along with “lack of prioritization” were the main challenges in recruiting older participants. Provision of health-related incentives including but not limited to access to new treatments and getting expert medical care seem to be the top-rated motivation to participate in vaccine clinical trials.

Conclusions:

The main challenges for recruiting PLW and children in vaccine trials involve safety and efficacy concerns, as well as the lengthy ethical and regulatory processes. For older adults, key issues include poor communication channels tailored to their needs, limited information, lack of prioritization, funding, infrastructure, and industry interest. Across all underrepresented groups, low awareness and poor communication about research opportunities were major barriers. Additionally, mobility issues affected older adults, while lack of motivation and incentives affected children, and low health literacy and provider uncertainty impacted PLW. Improving communication infrastructure and enhancing communication strategies with clear, tailored messages to build trust and motivate participation is essential to improve inclusion in vaccine research. Clinical Trial: Not applicable.


 Citation

Please cite as:

Tanriover MD, Poulimeneas D, Tsopela GC, Kopsidas I, Argyropoulos C, Di Marzo R, Valdenmaiier O, Jakobsen SF, Valle-Simon P, Carcas-Sansuan AJ, Olesen OF, Cornely OA, Pana ZD, Zaoutis TE, Akova M

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

JMIR Public Health Surveill 2026;12:e89025

DOI: 10.2196/89025

PMID: 41945868

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.